MIRA Pharmaceutical Shares Are Trading Higher After the Company's New Preclinical Data Showed That Ketamir-2 Achieved 60% Greater Efficacy Than the FDA-approved Gabapentin in Reducing Chemotherapy-induced Pain.
MIRA Pharmaceutical Shares Are Trading Higher After the Company's New Preclinical Data Showed That Ketamir-2 Achieved 60% Greater Efficacy Than the FDA-approved Gabapentin in Reducing Chemotherapy-induced Pain.
MIRA藥品股價上漲，公司新的臨床前數據顯示，Ketamir-2在減輕化療引起的疼痛方面的療效比獲得FDA批准的Gabapentin高出60%。
MIRA Pharmaceutical Shares Are Trading Higher After the Company's New Preclinical Data Showed That Ketamir-2 Achieved 60% Greater Efficacy Than the FDA-approved Gabapentin in Reducing Chemotherapy-induced Pain.
MIRA藥品股價上漲，公司新的臨床前數據顯示，Ketamir-2在減輕化療引起的疼痛方面的療效比獲得FDA批准的Gabapentin高出60%。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間